ArticleTranslational oncology2026
Shared genetic regulators and diagnostic biomarkers in gallbladder stone and cholangiocarcinoma: A comprehensive comparative transcriptomic analysis.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallbladder stone (GS) and cholangiocarcinoma (CHOL) are common biliary tract disorders that share certain clinical and pathological characteristics but exhibit distinct molecular hallmarks. While GS-related inflammation, cholestasis, and epithelial injury-repair responses may provide a biologically plausible link, the shared genetic mechanisms underlying the pathogenesis of both diseases remain largely unexplored. The aim of this study was to elucidate this shared genetic landscape using a comparative transcriptomic approach. We identified 671 and 5197 differentially expressed genes (DEGs) in the GS and CHOL datasets, respectively. Gene ontology and KEGG enrichment analysis of these DEGs revealed possible involvement in IL-17 signaling and bile acid metabolism. The overlap of the DEGs yielded 15 common genes, which were further refined to three core genes-CENPH, NRSN2, and SPDYC-using LASSO regression analysis. The expression levels of these core genes were validated across multiple datasets, and ROC analysis demonstrated that they exhibited robust diagnostic performance for distinguishing both GS and CHOL. The copy number variations and promoter methylation status of these core genes were also evaluated. Candidate drug compounds targeting these genes were predicted using the PubChem database, and a gene-compound interaction network was constructed to facilitate future therapeutic investigations. We further confirmed that CENPH was significantly upregulated in CHOL cell lines (HuCC-T1 and RBE) compared to normal human intrahepatic biliary epithelial cells. Subsequently, loss-of-function assays showed that CENPH was essential for the proliferation, migration, and invasion of CHOL cells. In conclusion, our findings provide new insights into the shared genetic regulators of GS and CHOL and highlight the potential for developing effective diagnostic tools and tailored therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.